An Overview of the Direct Thrombin Inhibitor Argatroban

@article{Walenga2002AnOO,
  title={An Overview of the Direct Thrombin Inhibitor Argatroban},
  author={Jeanine M. Walenga},
  journal={Pathophysiology of haemostasis and thrombosis},
  year={2002},
  volume={32 Suppl 3},
  pages={9-14}
}
Argatroban is a small molecule direct thrombin inhibitor. The main attributes of this synthetic drug are its rapid onset of anti-thrombin action, rapid reversibility of its anticoagulant effect, potent inhibition of clot-bound thrombin, absence of antibody formation and no need for initial dosage adjustment in patients with renal impairment. It is eliminated by hepatic metabolism. These properties make argatroban a predictable anticoagulant with intravenous use in a routine clinical setting… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Argatroban therapy in heparin-induced thrombocytopenia.

AACN advanced critical care • 2009
View 4 Excerpts
Highly Influenced

Effects of argatroban as an anticoagulant for intermittent veno-venous hemofiltration (IVVH) in patients at high risk of bleeding.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association • 2011
View 3 Excerpts
Highly Influenced

Direkte Thrombinhemmung

Herz Kardiovaskuläre Erkrankungen • 2005
View 3 Excerpts

References

Publications referenced by this paper.
Showing 1-10 of 45 references

Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions • 2002

Investigation of the interaction between argatroban and acetaminophen, lidocaine, or digoxin.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists • 2002

Antihirudin antibodies in patients with HIT treated with lepirudin: Incidence, effects on aPTT, and clinical relevance. Blood 2000;96:2373–2378

P Eichler, H-J Friesen, N Lubenow, B Jaeger, A Greinacher
2000

Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects

SK Swan, JV St. Peter, LJ Lambrecht, MJ Hursting
Pharmacotherapy • 2000

Similar Papers

Loading similar papers…